With the approvals of various targeted therapies including tyrosine kinase inhibitors to antibody–drug conjugates, the treatment landscape of patients with EGFR-mutant non-small cell lung cancer has drastically improved. The use of EGFR-targeted therapies has shifted to include not only advanced/ metastatic disease but also to early-stage non-small cell lung cancer. Novel therapy options have sought to address the need for effective agents against acquired resistance mechanisms in EGFR mutations. Further, the role of tyrosine kinase inhibitors against EGFR mutation in the perioperative setting has been most recently evaluated. With early outcomes, clinicians are met with the need to guide patients through various treatment regimens, and mature survival results are anticipated for several key trials. Of import, the growing focus on personalized treatment options based on outcomes, quality-of-life, toxicity, tolerability, and various disease-related factors warrants consideration. This review comprehensively describes frontline and subsequent-line therapy options for patients with early stage, unresectable/ locally advanced, and advanced/ metastatic stages of EGFR-mutant non-small cell lung cancer, including unprecedented therapeutic agents.
Vyas et al. (Sat,) studied this question.